QLG2065

QLG2065 is a semaglutide-based, once-weekly injectable glucagon-like peptide 1 receptor agonist being developed by Qilu Pharmaceutical as a biosimilar-equivalent product to Ozempic for glycemic control in adults with type 2 diabetes mellitus inadequately controlled on metformin.[1][4][7][12] As a long-acting GLP-1 analog, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite, thereby improving glycemic control and potentially supporting weight loss.[1][5] QLG2065 is in late-stage clinical development, including a Phase 3 trial directly comparing its efficacy and safety to Ozempic in patients with type 2 diabetes, positioning it for regulatory submission in China as an alternative semaglutide injection product.[1][4][7][12]

Other names

semaglutide injectionsemaglutide (Qilu Pharmaceutical)